Beijing Biostar Pharmaceuticals Announces Plan for On-Market H-Share Buy-back of up to 10%

Bulletin Express05-07

Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) disclosed a voluntary plan to repurchase its H shares on the open market, leveraging the general mandate granted at the 25 August 2025 annual general meeting. The mandate authorises the board to buy back a maximum amount equivalent to 10% of the company’s H shares then in issue.

The board resolution approved on 6 May 2026 sets the groundwork for periodic repurchases, contingent upon: 1. Regulatory clearance for foreign-exchange remittance in mainland China, and 2. Separate shareholder approval for amendments to the company’s Articles of Association covering share buy-backs.

Management stated that available financial resources are sufficient to undertake the programme without compromising balance-sheet strength. The initiative is positioned as a signal of confidence in the company’s outlook and a means of enhancing shareholder value.

Execution timing, volume and pricing will depend on prevailing market conditions and remain at the board’s sole discretion; the company cautioned that repurchases may vary or not occur at all. Investors are advised to exercise prudence when trading the shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188127627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188127627","market":"hk","top_or_hot":-1,"title":"Beijing Biostar Pharmaceuticals Announces Plan for On-Market H-Share Buy-back of up to 10%","media":"Bulletin Express","content":"<p>Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) disclosed a voluntary plan to repurchase its H shares on the open market, leveraging the general mandate granted at the 25 August 2025 annual general meeting. The mandate authorises the board to buy back a maximum amount equivalent to 10% of the company’s H shares then in issue.</p>\n<p>The board resolution approved on 6 May 2026 sets the groundwork for periodic repurchases, contingent upon:\n1. Regulatory clearance for foreign-exchange remittance in mainland China, and  \n2. Separate shareholder approval for amendments to the company’s Articles of Association covering share buy-backs.</p>\n<p>Management stated that available financial resources are sufficient to undertake the programme without compromising balance-sheet strength. The initiative is positioned as a signal of confidence in the company’s outlook and a means of enhancing shareholder value.</p>\n<p>Execution timing, volume and pricing will depend on prevailing market conditions and remain at the board’s sole discretion; the company cautioned that repurchases may vary or not occur at all. Investors are advised to exercise prudence when trading the shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Biostar Pharmaceuticals Announces Plan for On-Market H-Share Buy-back of up to 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Biostar Pharmaceuticals Announces Plan for On-Market H-Share Buy-back of up to 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-07 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) disclosed a voluntary plan to repurchase its H shares on the open market, leveraging the general mandate granted at the 25 August 2025 annual general meeting. The mandate authorises the board to buy back a maximum amount equivalent to 10% of the company’s H shares then in issue.</p>\n<p>The board resolution approved on 6 May 2026 sets the groundwork for periodic repurchases, contingent upon:\n1. Regulatory clearance for foreign-exchange remittance in mainland China, and  \n2. Separate shareholder approval for amendments to the company’s Articles of Association covering share buy-backs.</p>\n<p>Management stated that available financial resources are sufficient to undertake the programme without compromising balance-sheet strength. The initiative is positioned as a signal of confidence in the company’s outlook and a means of enhancing shareholder value.</p>\n<p>Execution timing, volume and pricing will depend on prevailing market conditions and remain at the board’s sole discretion; the company cautioned that repurchases may vary or not occur at all. Investors are advised to exercise prudence when trading the shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1188127627","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188127627","pubTimestamp":1778166161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) disclosed a voluntary plan to repurchase its H shares on the open market, leveraging the general mandate granted at the 25 August 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"北京映泰制药公布场内H股回购最多10%计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) disclosed a voluntary plan to repurchase its H shares on the open market, leveraging the general mandate granted at the 25 August 2025 annual general meeting. The mandate authorises the board to buy back a maximum amount equivalent to 10% of the company’s H shares then in issue.\nThe board resolution approved on 6 May 2026 sets the groundwork for periodic repurchases, contingent upon:\n1. Regulatory clearance for foreign-exchange remittance in mainland China, and  \n2. Separate shareholder approval for amendments to the company’s Articles of Association covering share buy-backs.\nManagement stated that available financial resources are sufficient to undertake the programme without compromising balance-sheet strength. The initiative is positioned as a signal of confidence in the company’s outlook and a means of enhancing shareholder value.\nExecution timing, volume and pricing will depend on prevailing market conditions and remain at the board’s sole discretion; the company cautioned that repurchases may vary or not occur at all. Investors are advised to exercise prudence when trading the shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188127627","isCrawlerRequest":true}